Stress-related mucosal disease

  • Mitchell J. Spirt
Article

Opinion statement

Stress-related mucosal disease (SRMD) includes stress-related injury (superficial mucosal damage) and stress ulcers (focal deep mucosal damage). Both types are caused by mucosal ischemia, and both show a propensity for the acid-producing corpus and fundus. Prophylaxis of stress ulcers may reduce major bleeding but, so far, has not been shown to improve survival. The most widely used drugs for stress-related injury are the intravenous histamine H2-receptor antagonists. Proton pump inhibitors (PPIs) are the most potent acid-suppressive pharmacologic agents. The available PPIs significantly increase gastric pH for up to 24 hours after one dose. Tolerance does not develop, and adverse effects are few. Preliminary studies have demonstrated a significant reduction in SRMD bleeding for patients receiving PPI prophylaxis. PPIs may become an effective tool for reducing the incidence of SRMD in critically ill patients.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Zandstra DF, Stoutenbeek CP: The virtual absence of stress-ulceration related bleeding in ICU patients receiving prolonged mechanical ventilation without any prophylaxis: a prospective cohort study. Intensive Care Med 1994, 20:335–340.PubMedCrossRefGoogle Scholar
  2. 2.
    Leung FW, Itoh M, Hirabayashi K, Guth PH: Role of blood flow in gastric and duodenal mucosal injury in the rat. Gastroenterology 1985, 88:281–289.PubMedGoogle Scholar
  3. 3.
    Spirt M, Guth PH, Leung FW, Randall G: Critically ill septic ICU patients have severe upper gastrointestinal mucosal ischemia. Gastroenterology 1995, 108:A326. This was the first report of critically ill patients in the ICU who did not have GI bleeding undergoing blood flow measurements. The authors demonstrated that blood flow in these patients was half that of normal controls.CrossRefGoogle Scholar
  4. 4.
    Peura DA, Johnson LF: Cimetidine for prevention and treatment of gastroduodenal mucosal lesions in patients in an intensive care unit. Ann Intern Med 1985, 103:173–177.PubMedGoogle Scholar
  5. 5.
    Lucas CE, Sugawa C, Riddle J, et al.: Natural history and surgical dilemma of “stress” gastric bleeding. Arch Surg 1971, 102:266–273.PubMedGoogle Scholar
  6. 6.
    Zuckerman GR, Shuman R: Therapeutic goals and treatment options for prevention of stress ulcer syndrome. Am J Med 1987, 83(Suppl 6A):29–35.PubMedCrossRefGoogle Scholar
  7. 7.
    Schuster DP, Rowley H, Feinstein S, et al.: Prospective evaluation of the risk of upper gastrointestinal bleeding after admission to a medical intensive care unit. Am J Med 1984, 76:623–630. This paper was one of the first papers to demonstrate that the two major risk factors for stress-related bleeding are respiratory failure and coagulapathy. The authors also showed that the risk of death was 64% in those patients who bled versus 9% in those who did not bleed.PubMedCrossRefGoogle Scholar
  8. 8.
    Cook DJ, Fuller HD, Guyatt GH, et al.: Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med 1994, 330:377–381. In a prospective multicenter study, the authors found that respiratory failure and coagulopathy were strong independent risk factors for the development of clinically important GI bleeding. Of 2252 study patients, 847 had one or more of the risk factors; 31 (3.7%) had clinically important bleeding. This paper identified the two most important risk factors for stress-related bleeding. The study advises that we have been overtreating this disease entity because the risk is smaller than we previously believed.PubMedCrossRefGoogle Scholar
  9. 9.
    Harris SK, Bone RC, Ruth WE: Gastrointestinal hemorrhage in patients in a respiratory intensive care unit. Chest 1977, 72:301–304.PubMedGoogle Scholar
  10. 10.
    Fusamoto H, Hagiwara H, Meren H, et al.: A clinical study of acute gastrointestinal hemorrhage associated with various shock states. Am J Gastroenterol 1991, 86:429–433.PubMedGoogle Scholar
  11. 11.
    Czaja AJ, McAlhany JC, Pruitt BAJ. Acute gastroduodenal disease after thermal injury: an endoscopic evaluation of incidence and natural history. N Engl J Med 1974;291:925–929.PubMedCrossRefGoogle Scholar
  12. 12.
    Goodman AA, Frey CF: Massive upper gastrointestinal hemorrhage following surgical operations. Ann Surg 1968, 167:180–184.PubMedCrossRefGoogle Scholar
  13. 13.
    Cappell MS, Iacovone FMJ: Safety and efficacy of esophagogastroduodenoscopy after myocardial infarction. Am J Med 1999, 106:29–35.PubMedCrossRefGoogle Scholar
  14. 14.
    Brown TH, Davidson PF, Larson GM: Acute gastritis occurring within 24 hours of severe head injury. Gastrointest Endosc 1989, 35:37–40.PubMedGoogle Scholar
  15. 15.
    Marrone GC, Silen W: Pathogenesis, diagnosis and treatment of acute gastric mucosal lesions. Clin Gastroenterol 1984, 13:635–650.PubMedGoogle Scholar
  16. 16.
    Morris DL, Markham SJ, Beechey A, et al.: Ranitidinebolus or infusion prophylaxis for stress ulcer. Crit Care Med 1988, 16:229–232.PubMedCrossRefGoogle Scholar
  17. 17.
    Maier RV, Mitchell D, Gentilello L: Optimal therapy for stress gastritis. Ann Surg 1994, 220:353–360.PubMedCrossRefGoogle Scholar
  18. 18.
    Spirt MJ: Acute Care of the Abdomen, edn 1. Baltimore: Williams & Wilkins; 1998:73–83.Google Scholar
  19. 19.
    Chernov MS, Hale HWJ, Wood M: Prevention of stress ulcers. Am J Surg 1971, 122:674–677.PubMedCrossRefGoogle Scholar
  20. 20.
    Macdougall BRD, Bailey RJ, Williams R: H2-receptor antagonists and antacids in the prevention of acute gastrointestinal haemorrhage in fulminant hepatic failure: two controlled trials. Lancet 1977, 19:617–619.CrossRefGoogle Scholar
  21. 21.
    Hastings PR, Skillman JJ, Bushnell LS, Silen W: Antacid titration in the prevention of acute gastrointestinal bleeding: a controlled, randomized trial in 100 critically ill patients. N Engl J Med 1978, 298:1041–1045.PubMedCrossRefGoogle Scholar
  22. 22.
    Jones RH, Rudge CJ, Bewick M, et al.: Cimetidine: prophylaxis against upper gastrointestinal haemorrhage after renal transplantation. BMJ 1978, 1:398–400.PubMedGoogle Scholar
  23. 23.
    Ostro MJ, Russell JA, Soldin SJ, et al.: Control of gastric pH with cimetidine: boluses versus primed infusions. Gastroenterology 1985, 89:532–537.PubMedGoogle Scholar
  24. 24.
    Siepler JK, Trudeau W, Petty DE: Use of continuous infusion of histamine2-receptor antagonists in critically ill patients. DICP 1989, 23(Suppl 10):S40-S43.PubMedGoogle Scholar
  25. 25.
    Mathôt RAA, Geus WP: Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: characterization of tolerance. Clin Pharmacol Ther 1999, 66:140–151.PubMedGoogle Scholar
  26. 26.
    Martin LF, Booth FV, Karlstadt RG, et al.: Continuous intravenous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia. Crit Care Med 1993, 21:19–30.PubMedCrossRefGoogle Scholar
  27. 27.
    Jansen JBMJ, Lundborg P, Baak LC, et al.: Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man. Gut 1988, 29:75–80.PubMedGoogle Scholar
  28. 28.
    Cederberg C, Thomson ABR, Mahachai V, et al.: Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. Gastroenterology 1992, 103:913–918.PubMedGoogle Scholar
  29. 29.
    Lind T, Moore M, Olbe L: Intravenous omeprazole: effect on 24-h intragastric pH in duodenal ulcer patients. Digestion 1986, 34:78–86.PubMedCrossRefGoogle Scholar
  30. 30.
    Lind T, Cederberg C, Ekenved G, et al.: Effect of omeprazole-a gastric proton pump inhibitor-on pentagastrin stimulated acid secretion in man. Gut 1983, 24:270–276.PubMedGoogle Scholar
  31. 31.
    Lasky MR, Metzler MH, Phillips JO: A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma 1998, 44:527–533.PubMedGoogle Scholar
  32. 32.
    Phillips JO, Metzler MH, Palmieri TL, et al.: A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med 1996, 24:1793–1800.PubMedCrossRefGoogle Scholar
  33. 33.
    Shin JM, Besancon M, Simon A, Sachs G: The site of action of pantoprazole in the gastric H+/K+-ATPase. Biochim Biophys Acta 1993, 1148:223–233.PubMedCrossRefGoogle Scholar
  34. 34.
    Netzer P, Gaia C, Sandoz M, et al.: Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol 1999, 94:351–357.PubMedGoogle Scholar
  35. 35.
    Pisegna JR: Switching between intravenous and oral pantoprazole. J Clin Gastroenterol 2001, 32:27–32.PubMedCrossRefGoogle Scholar
  36. 36.
    Pisegna JR, Martin P, McKeand W, et al.: Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study. Am J Gastroenterol 1999, 94:2874–2880.PubMedCrossRefGoogle Scholar
  37. 37.
    Zinner MJ, Rypins EB, Martin LR, et al.: Misoprostol versus antacid titration for preventing stress ulcers in postoperative surgical ICU patients. Ann Surg 1989, 210:590–595.PubMedCrossRefGoogle Scholar
  38. 38.
    Halm U, Halm F, Thein D, et al.: Helicobacter pylori infection: a risk factor for upper gastrointestinal bleeding after cardiac surgery? Crit Care Med 2000, 28:110–113.PubMedCrossRefGoogle Scholar
  39. 39.
    Kollef MH: Ventilator-associated pneumonia: a multivariate analysis. JAMA 1993, 270:1965–1970.PubMedCrossRefGoogle Scholar
  40. 40.
    Cook D, Heyland D, Griffith L, et al.: Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. Crit Care Med 1999, 27:2812–2817.PubMedCrossRefGoogle Scholar
  41. 41.
    Daschner F, Kappstein I, Engels I, et al.: Stress ulcer prophylaxis and ventilation pneumonia: prevention by antibacterial cytoprotective agents? Infect Control Hosp Epidemiol 1988, 9:59–65.PubMedCrossRefGoogle Scholar
  42. 42.
    Eddleston JM, Vohra A, Scott P, et al.: A comparison of the frequency of stress ulceration and secondary pneumonia in sucralfate- or ranitidine-treated intensive care unit patients. Crit Care Med 1991, 19:1491–1496.PubMedCrossRefGoogle Scholar
  43. 43.
    Kappstein I, Schulgen G, Friedrich T, et al.: Incidence of pneumonia in mechanically ventilated patients treated with sucralfate or cimetidine as prophylaxis for stress bleeding: bacterial colonization of the stomach. Am J Med 1991, 91:125S-131S.PubMedCrossRefGoogle Scholar
  44. 44.
    Tryba M, Mantey-Stiers F: Antibacterial activity of sucralfate in human gastric juice. Am J Med 1987, 83:125–127.PubMedCrossRefGoogle Scholar
  45. 45.
    Driks MR, Craven DE, Celli BR, et al.: Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers: the role of gastric colonization. N Engl J Med 1987, 317:1376–1382.PubMedCrossRefGoogle Scholar
  46. 46.
    Tryba M: Sucralfate versus antacids or H2-antagonists for stress ulcer prophylaxis: a meta-analysis on efficacy and pneumonia rate. Crit Care Med 1991, 19:942–949.PubMedCrossRefGoogle Scholar
  47. 47.
    Prod’hom G, Leuenberger P, Koerfer J, et al.: Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer: a randomized controlled trial. Ann Intern Med 1994, 120:653–662.PubMedGoogle Scholar
  48. 48.
    Levy MJ, Seelig CB, Robinson NJ, Ranney JE: Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci 1997, 42:1255–1259.PubMedCrossRefGoogle Scholar
  49. 49.
    Cook D, Guyatt G, Marshall J, et al.: A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. N Engl J Med 1998, 338:791–797. This study was the largest and most authoritative trial demonstrating that acid suppression with H2 antagonists does not increase the nosocomial pneumonia rate compared with sucralfate.PubMedCrossRefGoogle Scholar
  50. 50.
    Ben-Menachem T, McCarthy BD, Fogel R, et al.: Prophylaxis for stress-related gastrointestinal hemorrhage: a cost effective analysis. Crit Care Med 1996, 24:338–345.PubMedCrossRefGoogle Scholar
  51. 51.
    Azevedo JR, Soares MG, Silva G, Palacio G: Prevention of stress ulcer bleeding in high risk patients: comparison of three drugs [abstract]. Crit Care Med 1999, 27:A145.CrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Mitchell J. Spirt
    • 1
  1. 1.Los AngelesUSA

Personalised recommendations